Valuation: Theracryf Plc

Market Cap 6.67M 5.86M 5.4M 5.05M 9.47M 630M 9.65M 64.8M 25.1M 310M 25.06M 24.51M 1.08B P/E 2026 *
-1.56x
P/E 2027 * -1.91x
Enterprise Value 4.52M 3.97M 3.66M 3.42M 6.42M 427M 6.54M 43.92M 17.01M 210M 16.98M 16.61M 731M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
54.35%
Yield 2026 *
-
Yield 2027 * -
Current month-2.08%
1 month+2.17%
3 months+14.63%
6 months+17.50%
Current year+17.50%
1 week 0.23
Extreme 0.23
0.24
1 month 0.22
Extreme 0.22
0.26
Current year 0.18
Extreme 0.182
0.27
1 year 0.18
Extreme 0.175
0.3
3 years 0.18
Extreme 0.175
3.4
5 years 0.18
Extreme 0.175
9
10 years 0.18
Extreme 0.175
35
Manager TitleAgeSince
Chief Executive Officer 64 01/10/2020
Director of Finance/CFO - 05/09/2023
Chief Tech/Sci/R&D Officer - 01/05/2021
Director TitleAgeSince
Director/Board Member - 14/10/2015
Director/Board Member 64 01/10/2020
Director/Board Member - 01/01/2024
Date Insider Type Main position Quantity % Market Cap.
16/10/25
Tracarta Ltd.
BuyCompany 7,342,296 0.3448%
22/05/25Others

Director

422,727,272 19.8499%
04/03/25Buy

Chief Operating Officer

1,500,000 0.2945%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-7.84%-92.42% 6.65M
+4.43%+2.49%+61.83%+115.25% 52.88B
+1.58%+14.12%+72.87%+85.18% 50.98B
-0.23%-0.98%-14.12%-16.00% 22.81B
+0.98%+9.05%-0.36%+423.40% 22.43B
-0.73%+6.83%+31.36%-14.59% 17.01B
+0.88%+5.78%+30.82%-34.26% 15.91B
+3.02%+12.74%+143.33%+308.04% 13.58B
+0.68%+2.54%+22.28%+168.03% 13.29B
+0.44%+5.61%+27.51% - 12.56B
Average +1.10%+5.63%+36.77%+104.74% 22.15B
Weighted average by Cap. +1.75%+6.70%+46.36%+120.58%

Financials

2026 *2027 *
Net sales - -
Net income -3.35M -2.94M -2.71M -2.54M -4.76M -316M -4.84M -32.54M -12.6M -156M -12.58M -12.31M -542M -3.43M -3.01M -2.78M -2.6M -4.87M -324M -4.96M -33.3M -12.9M -160M -12.88M -12.6M -554M
Net Debt -2.15M -1.89M -1.74M -1.63M -3.05M -203M -3.11M -20.89M -8.09M -100M -8.08M -7.9M -348M 453K 398K 367K 343K 644K 42.79M 655K 4.4M 1.71M 21.09M 1.7M 1.67M 73.3M
Logo Theracryf Plc
TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.
Employees
9
Date Price Change Volume
25/06/26 GBX 0.2350 0.00% 798,460
24/06/26 GBX 0.2350 0.00% 3,271,066
23/06/26 GBX 0.2350 0.00% 3,809,088
22/06/26 GBX 0.2350 0.00% 3,391,828
19/06/26 GBX 0.2350 0.00% 1,105,212
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.003106USD
Average target price
0.0431USD
Spread / Average Target
+1,289.14%

Annual profits - Rate of surprise